Clinical Trial Testing Nausea Treatment as Way of Preventing Alzheimer’s in Early-stage Patients Underway in Europe

Clinical Trial Testing Nausea Treatment as Way of Preventing Alzheimer’s in Early-stage Patients Underway in Europe
Immungenetics AG is conducting a Phase 2 proof-of-concept clinical trial to investigate whether thiethylperazine — a treatment for nausea and vomiting in use since the 1960s — might help people with Alzheimer’s disease by working to slow or stop the early events that underlie disease progression. Thiethylperazine, sold for years under the brand name Torecan, was approved

Knowledge is power when living with alzheimers.

Get access to the web’s leading Alzheimer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *